NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: JENBURPH · data 2026-11-01
Jenburkt Pharmaceuticals Ltd
In plain words
Price: 20.5% below its 52-week high of ₹1,073.9.
Delivery: 83.2% of traded shares were kept for delivery over the last 10 sessions, against 83.6% over the last 52.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹169 cr |
| Net profit (last 12 months) | ₹33 cr |
| Sales growth, 3 years (yearly) | 7.3% |
| Profit growth, 3 years (yearly) | 12.2% |
At a glance
P/E 11.5, dividend yield 2.4%. Price relative to earnings and book value (low is cheaper, not better).
ROE 18.8%, ROCE 22.7%, operating margin 22.4%: how much profit it earns on the money it uses.
Debt/equity 0.01, Profit growth 12.2% and sales growth 7.3% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (18.8%).
- Healthy operating margin (22.4%).
- Pays a dividend yielding 2.4%.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
18/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 67.8% over the last 20 sessions vs 86.9% in the 40 before (0.78x); shares delivered per day 1.19x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Dividend
- 28 Oct 26Insider SAST disclosure: Counter Cyclical Investments Pvt Lt… acquired 326 shares -0.4% next session
- 28 Aug 26Dividend Dividend ₹20.7 (ex-date) +1.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Jenburkt Pharmaceuticals Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is Jenburkt Pharmaceuticals Ltd's P/E ratio?
About 11.5, based on the last 12 months' earnings and a price of ₹853.6 (data 2026-11-01).
What is the 52-week high and low of Jenburkt Pharmaceuticals Ltd?
The 52-week high is ₹1,073.9 and the 52-week low is ₹845.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Jenburkt Pharmaceuticals Ltd | ₹853.6 | ₹377 cr | 11.5 | — | 18.8% | 22.7% | 0.01 | -18.1% |
| Infinium Pharmachem Ltd. | ₹281 | ₹438 cr | 36 | 3.6 | 10.5% | 13.5% | 0.19 | +8.0% |
| Albert David Ltd | ₹762.8 | ₹435 cr | 19.3 | — | -0.4% | 0.3% | 0.08 | -11.0% |
| Medicamen Biotech Limited | ₹256.2 | ₹347 cr | 31.3 | — | 3.9% | 5.5% | 0.18 | -27.6% |
| Aarey Drugs & Pharmaceuticals Ltd. | ₹106.26 | ₹298 cr | 72.4 | — | 2.7% | 6% | 0.33 | +15.4% |
| Ambalal Sarabhai Enterprises Limited | ₹34.99 | ₹268 cr | 19.8 | — | 11.9% | 9.4% | 0.36 | +8.3% |
Compare JENBURPH with INFINIUM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open JENBURPH in NSE Scanner →